Manan Pandya, DO
Internal Medicine · Monroe, NJNPI 1255659835
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 794 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 57 manufacturers, the largest accounting for just 15.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $2,758 and has fallen 64.5% since, to $979 in 2025. Among internal medicine clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 794 payments — averaging $15.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Novo Nordisk$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$917
- AbbVie$912
- Bayer$825
- Boehringer Ingelheim$811
- plus $6K from 51 others
What the payments were for
- Food & beverage$12,546100%
- Education$240%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,570 in reported general payments places this provider in the 95th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Azelastine Hcl | 66 | $1,214 |
| Fluticasone Propionate | 84 | $998 |
| Neomycin-Polymyxin-HcNeomycin/Polymyxin B/Hydrocort | 16 | $911 |
| Atorvastatin Calcium | 72 | $879 |
| Celecoxib | 20 | $786 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 38 | $710 |
| Cefdinir | 45 | $682 |
| Azithromycin | 168 | $682 |
| Diclofenac Sodium | 21 | $630 |
| Methylprednisolone | 96 | $629 |
| Amlodipine Besylate | 77 | $624 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 40 | $490 |
| Trazodone Hcl | 18 | $465 |
| Pantoprazole Sodium | 27 | $410 |
| Rosuvastatin Calcium | 24 | $385 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Monroe
- David ShulkinMorristown$1.7M
- Howard UdermanLakewood$955K
- Darshi SunderamEast Orange$530K
- Annika DrongeEmerson$401K
- Stephen MarcellaNew Brunswick$331K
- Viju VijaysadanKinnelon$325K
- Mark MonaneWoodcliff Lake$268K
- Martin BedigianLivingston$240K
- Rameck HuntPlainsboro$217K
- Angel LazoSecaucus$195K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.